Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs

Bone Marrow Transplantation

Volumn 47, Issue 9, 2012, Pages 1229-1234

  Broen, K ^a   Greupink Draaisma, A ^a   Fredrix, H ^a   Schaap, N ^a   Dolstra, H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cytotoxic T cells; DCs; graft versus tumor; immunotherapy; minor histocompatibility antigen; multiple myeloma

Indexed keywords

CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; FLUDARABINE; HLA A3 ANTIGEN; KEYHOLE LIMPET HEMOCYANIN; M PROTEIN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CASE REPORT; CD8+ T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; FEVER; GRAFT RECIPIENT; HUMAN; INJECTION SITE INDURATION; LYMPHOCYTE CLONE; MALE; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REDUCED INTENSITY CONDITIONING; SIGNAL TRANSDUCTION; T CELL DEPLETION; TUMOR LOCALIZATION; TUMOR REGRESSION;

ADULT; DENDRITIC CELLS; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; MALE; MULTIPLE MYELOMA; RECEPTORS, ANTIGEN, T-CELL;

EID: 84865962487     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.258     Document Type: Article

References (22)

1. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362-4364. (Pubitemid 38685385)
2. Zeiser R, Bertz H, Spyridonidis A, Houet L, Finke J. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant 2004; 34: 923-928. (Pubitemid 39600107)
3. Levenga H, Levison-Keating S, Schattenberg AV, Dolstra H, Schaap N, Raymakers RA. Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. Bone Marrow Transplant 2007; 40: 355-359. (Pubitemid 47202420)
4. Levenga H, Schaap N, Maas F, Esendam B, Fredrix H, Greupink-Draaisma A et al. Partial T cell-depleted allogeneic stem cell transplantation following reducedintensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Biol Blood Marrow Transplant 2010; 16: 320-332.
5. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998; 279: 1054-1057. (Pubitemid 28113311)
6. van Bergen CA, Kester MG, Jedema I, Heemskerk MH, van Luxemburg-Heijs SA, Kloosterboer FM et al. Multiple myeloma-reactive T cells recognize an activationinduced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood 2007; 109: 4089-4096. (Pubitemid 46641765)
7. Slager EH, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Kloosterboer FM, Kester MG et al. Identification of the angiogenic endothelialcell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 2006; 107: 4954-4960. (Pubitemid 43882650)
8. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSEbased assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 2004; 103: 2677-2682. (Pubitemid 38393024)
9. Overes IM, de RB, van Horssen-Zoetbrood A, Fredrix H, de Graaf AO, Jansen JH et al. Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. Br J Haematol 2008; 141: 799-807. (Pubitemid 351724862)
10. Meijerink J, Mandigers C, van de LL, Tonnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 2001; 3: 55-61. (Pubitemid 32440243)
11. Broen K, Vos JC, van Bergen CA, Fredrix H, Greupink-Draaisma A, Kester M et al. A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen ZAPHIR. PLoS One 2011; 6: e21699.
12. Meadows L, Wang W, den Haan JM, Blokland E, Reinhardus C, Drijfhout JW et al. The HLA-A 0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997; 6: 273-281. (Pubitemid 27148594)
13. Wang W, Meadows LR, den Haan JM, Sherman NE, Chen Y, Blokland E et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269: 1588-1590.
14. Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graftversus-host disease and graft-versus-leukemia. Blood 2007; 110: 9-17. (Pubitemid 47026813)
15. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997; 157: 125-140. (Pubitemid 27303125)
16. Kircher B, Stevanovic S, Urbanek M, Mitterschiffthaler A, Rammensee HG, Grunewald K et al. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br J Haematol 2002; 117: 935-939. (Pubitemid 34639258)
17. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1-or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742-2747. (Pubitemid 36297569)
18. Melenhorst JJ, Scheinberg P, Chattopadhyay PK, Gostick E, Ladell K, Roederer M et al. High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. Blood 2009; 113: 2238-2244.
19. Palendira U, Chinn R, Raza W, Piper K, Pratt G, Machado L et al. Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow. Blood 2008; 112: 3293-3302.
20. Fujii S, Shimizu K, Fujimoto K, Kiyokawa T, Tsukamoto A, Sanada I et al. Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk Lymphoma 2001; 42: 357-369. (Pubitemid 32725591)
21. Kitawaki T, Kadowaki N, Kondo T, Ishikawa T, Ichinohe T, Teramukai S et al. Potential of dendritic cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide-and keyhole limpet hemocyanin-pulsed, donor-derived dendritic cell vaccine for acute myeloid leukemia. Am J Hematol 2008; 83: 315-317. (Pubitemid 351458011)
22. Tatsugami K, Eto M, Harano M, Nagafuji K, Omoto K, Katano M et al. Dendritic-cell therapy after non-myeloablative stem-cell transplantation for renal-cell carcinoma. Lancet Oncol 2004; 5: 750-752. (Pubitemid 39646785)